1. Extended Half-life Factor Products in the Management of Hemophilia

3. Program Goal

4. Overview of New Factor Concentrates

5. Updates on Fc Fusion Protein Approach in Hemophilia A and B

6. Real-world Data With Recombinant Factor VIII Fc Fusion Protein

7. Investigational EHLs: Phase 3 Results

8. Other Novel Products

9. Patient Education

10. Identifying Candidates for EHLs

11. Pharmacokinetic Studies

12. Practice Issues

13. Adherence

14. Inhibitors

15. Prophylaxis Dosing

16. Summary

17. Abbreviations

18. References

19. References (cont)

20. References (cont)

21. References (cont)